FDA weighs updated kids’ pneumococcal shot

updated 1:54 p.m. ET Nov. 16, 2009

WASHINGTON - The Food and Drug Administration is weighing whether to approve an updated version of Pfizer's best-selling anti-infection vaccine for children, despite company studies that failed to meet certain goals.

The Prevnar 13 vaccine reduces risk of infection by 13 varieties of pneumococcal disease, which causes ear infections, meningitis and pneumonia. The new version of the vaccine protects against six more varieties of the disease.

But FDA reviewers say in online documents that company studies failed to meet effectiveness goals for three types of pneumococcal disease.

The FDA will ask a panel of outside vaccine experts to weigh in on the results at a meeting Wednesday. The agency is not required to follow the group's advice, though it usually does.

Also in msnbc.com Health   Docs to patients: Pay up or lose care   Two-tiered medicine: Clinics with 2 doors What food cravings reveal about you 6 celebrity fad diets you won't believe Body Odd: Phantom smells may mean trouble   Animal Tracks: Eye candy for animal lovers

MORE FROM KIDS AND PARENTING

Kids and parenting Section Front

Kids watching hours of TV at home daycare Biggest child-killers: pneumonia and diarrhea 1 formerly conjoined twin talking after surgery FDA panel OKs new kids’ pneumococcal shot Toxic toys? Health group finds high lead levels Sex infections still rising, especially in teens FDA weighs updated kids’ pneumococcal shot Twins joined at head successfully separated Newsweek: Why grandma may play favorites It’s a boy? Disappointment plagues some moms Kids and parenting Section Front   Add Kids and parenting headlines to your news reader: